|
|
|
|
|
|
by rflrob
1980 days ago
|
|
|
I'm sure they would, but bear in mind that the costs are likely going to be much higher for an MS vaccine than for nCov2, due to the economies of scale that the latter has. Insurance companies will still probably love a one-time $20,000 (or whatever number they can justify) treatment compared to ongoing costs. |
|
|